Tianmu Pharmaceutical announced that in the third quarter of 2026, it achieved operating income of 504.259 million yuan, a year-on-year decrease of 8.88%; net profit to mother was 1.8038 million yuan, a year-on-year decrease of 54.46%. The first three quarters of 2026 achieved operating income of 150 million yuan, a year-on-year decrease of 5.76%; net profit to mother was 8.106 million yuan, a year-on-year decrease of 42.93%; net profit after deducting non-return to mother was 1.844,400 yuan, a year-on-year decrease of 83.05%. The company's compound fresh bamboo extract has resumed production. This product is the company's focus on cultivating OTC varieties. The controlling shareholder plans to publicly solicit and transfer 20% of the company's shares, which may result in changes in the controlling shareholder and actual controller, and approval from the competent authority is still required.

Tianmu Pharmaceutical announced that in the third quarter of 2026, it achieved operating income of 504.259 million yuan, a year-on-year decrease of 8.88%; net profit to mother was 1.8038 million yuan, a year-on-year decrease of 54.46%. The first three quarters of 2026 achieved operating income of 150 million yuan, a year-on-year decrease of 5.76%; net profit to mother was 8.106 million yuan, a year-on-year decrease of 42.93%; net profit after deducting non-return to mother was 1.844,400 yuan, a year-on-year decrease of 83.05%. The company's compound fresh bamboo extract has resumed production. This product is the company's focus on cultivating OTC varieties. The controlling shareholder plans to publicly solicit and transfer 20% of the company's shares, which may result in changes in the controlling shareholder and actual controller, and approval from the competent authority is still required.